Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors (KSDH)

This study is currently recruiting participants.
Verified July 2011 by Odense University Hospital
Sponsor:
Collaborators:
Alice Brenaa Foundation
Hede Nielsen Foundation
Overlægerådets legatudvalg
University of Southern Denmark
Information provided by:
Odense University Hospital
ClinicalTrials.gov Identifier:
NCT00915928
First received: June 3, 2009
Last updated: July 22, 2011
Last verified: July 2011

June 3, 2009
July 22, 2011
July 2009
June 2016   (final data collection date for primary outcome measure)
Recurrence of chronic subdural hematoma after surgical removal [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00915928 on ClinicalTrials.gov Archive Site
Composition of chronic subdural hematoma fluid [ Time Frame: Months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors
Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors

The project aims at investigating if treatment with the Angiotensin Converting Enzyme inhibitor Coversyl (perindopril) for 3 months after surgery for chronic subdural hematoma will decrease the risc of recurrence.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hematoma, Subdural, Chronic
  • Drug: Perindopril
    2,5 mg daily for 3 months
  • Drug: Placebo
  • Active Comparator: ACE inhibitor
    Intervention: Drug: Perindopril
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
Not Provided
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with chronic subdural hematoma that needs surgical evacuation
  2. Age > 18 year

Exclusion Criteria:

  1. Lack of compliance
  2. Kidney artery stenosis
  3. Stenosis of the aorta
  4. Severely decreased kidney function
  5. Allergy or intolerance/contraindications toward ACE inhibitors
  6. Already in ACE inhibitor treatment
  7. Coagulopathies
  8. Malignant disorders
  9. Fertile women
  10. Other neurological disorders
  11. Treatment with pharmaceuticals contraindicating treatment with ACE inhibitors
Both
18 Years and older
No
Contact: Frantz Rom Poulsen, MD, PhD +45 25306791 frantzrom@hotmail.com
Contact: Morten Søe, MD +45 66113333 MOS28.OUH-POST1@ouh.fyns-amt.dk
Denmark
 
NCT00915928
Chronic Subdural Hematoma, Eudra CT nummer 2009-010058-37
Yes
Frantz Rom Poulsen, MD, PhD, Department of Neurosurgery, Odense University Hospital, Odense, Denmark
Odense University Hospital
  • Alice Brenaa Foundation
  • Hede Nielsen Foundation
  • Overlægerådets legatudvalg
  • University of Southern Denmark
Principal Investigator: Frantz Rom Poulsen, MD, PhD Department of Neurosurgery, Odense University Hospital
Odense University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP